Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

157
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
157
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

953
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
953
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

119
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
119
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

94
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

351
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
351
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

129
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
129

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer.

Cell death & disease·2025
Same author

Inflammation Barrier Role of Piezo1 in Chondrocytes under Aberrant Loading.

Journal of dental research·2025
Same author

Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Magnetic Monopole Pair Production in Ultraperipheral Pb+Pb Collisions at sqrt[s_{NN}]=5.36  TeV with the ATLAS Detector at the LHC.

Physical review letters·2025
Same author

Simultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS Detector.

Physical review letters·2025
Same journal

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants.

The pharmacogenomics journal·2026
Same journal

Beyond the 'Pregnancy Black Box': a global roadmap for artificial intelligence-driven pharmacogenomics in maternal-neonatal health.

The pharmacogenomics journal·2026
Same journal

The association of ABCB1, CYP2C19 and CYP2C9 combined activity with clopidogrel resistance in patients with recurrent ischemic stroke.

The pharmacogenomics journal·2026
Same journal

Development and validation of an open data model for pharmacogenetics to enable semantic interoperability in clinical practice.

The pharmacogenomics journal·2026
Same journal

Finasteride, pharmacogenomics, and suicide risk: a public health concern.

The pharmacogenomics journal·2026
Same journal

Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.

The pharmacogenomics journal·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.9K

Using local multiplicity to improve effect estimation from a hypothesis-generating pharmacogenetics study.

W Zou1, H Ouyang2

  • 1Biostatistics, Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.

The Pharmacogenomics Journal
|March 25, 2015
PubMed
Summary
This summary is machine-generated.

A new method, multiple estimation adjustment (MEA), reduces overestimation in pharmacogenetics research. This approach corrects selection bias in hypothesis-generating studies, improving effect estimate accuracy.

More Related Videos

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.5K
Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

40.1K

Related Experiment Videos

Last Updated: Apr 15, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.9K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.5K
Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

40.1K

Area of Science:

  • Genetics
  • Statistical genetics
  • Pharmacogenetics

Background:

  • Hypothesis-generating studies (HGS) in pharmacogenetics often suffer from selection bias.
  • This bias leads to overestimation of effect sizes, complicating downstream analysis.
  • Accurate effect size estimation is crucial for reliable genetic association studies.

Purpose of the Study:

  • To introduce a novel method, multiple estimation adjustment (MEA), for correcting selection bias in pharmacogenetics.
  • To evaluate the performance of MEA compared to existing methods in simulated HGS settings.
  • To improve the reliability of genetic effect estimates derived from HGS.

Main Methods:

  • MEA employs a hierarchical Bayesian approach to model and adjust individual effect estimates.
  • It shrinks maximal likelihood estimates (MLE) towards a regional effect, accounting for local multiplicity.
  • The method's performance was compared against naive MLE and conditional likelihood adjustment (CLA) using simulated data.

Main Results:

  • MEA effectively reduced mean square errors (MSE) for null effects, both with and without selection bias.
  • The method demonstrated a clear advantage over CLA in scenarios with extreme MLE estimates from null effects under lenient selection thresholds.
  • These advantages were particularly notable in small sample sizes, common in top pharmacogenetics associations.

Conclusions:

  • Multiple estimation adjustment (MEA) offers a robust solution for correcting selection bias in pharmacogenetics HGS.
  • MEA improves the accuracy of effect size estimation, outperforming existing methods in specific common scenarios.
  • This advancement is vital for enhancing the validity of findings from exploratory genetic research.